Cognitive impairment is a core symptom domain of schizophrenia. The effect of antipsychotics,
the cornerstone of treatment in schizophrenia, on this domain is not fully clear. There is …

This guideline update reflects substantial advances in the epidemiology, determinants,
pathophysiology, assessment, prevention and treatment of obesity, and shifts the focus of obesity …

The American Medical Association recently recognized obesity as both an illness and a
leading cause of preventable death and chronic disease. This association is not only linked to …

The gut microbiome (GMB) plays an important role in developmental processes and has
been implicated in the etiology of psychiatric disorders. However, the relationship between …

Background: Antipsychotic-induced weight gain (AIWG) and other adverse metabolic effects
represent serious side effects faced by many patients with psychosis that can lead to …

Aims To evaluate if glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) reduce
antipsychotic‐associated body weight gain in patients with schizophrenia, when compared to controls…

Opinion Statement Interest in the negative symptoms of schizophrenia has increased rapidly
over the last several decades, paralleling a growing interest in functional, in addition to …

There is general agreement that the acute suppression of hepatic glucose production by
insulin is mediated by both a direct and an indirect effect on the liver. There is, however, no …

This paper describes the development of the knowledge base expert system denoted as Sewer
Cataloging, Retrieval and Prioritization System. This computer support system prioritizes …

A substantial and diverse body of literature suggests that the pathophysiology of schizophrenia
is related to deficits of bioenergetic function. While antipsychotics are an effective therapy …